{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:05:32Z","timestamp":1792598732772,"version":"4.5.0"},"reference-count":21,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"unspecified","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,2,23]]},"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Anti-programmed cell death protein 1 (PD-1) immunotherapy has revolutionized the treatment of stage III and IV melanoma. Real-world data on its resistance is needed to facilitate the development of combinatorial approaches to overcome anti-PD-1 resistance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To characterize anti-PD-1 resistance and assess whether progressive disease assigned by clinicians is concordant with scan data assessed by independent central reviewers (ICR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A retrospective chart review was conducted in adult patients with stage III\/IV melanoma who initiated anti-PD-1 therapy from January 2018 until 12 months before the start of data collection at 22 sites across six countries. Primary resistance and late relapse in the adjuvant setting, and primary, secondary resistance, and late progression in the advanced setting were assigned using\n                      <jats:italic>Society for Immunotherapy of Cancer<\/jats:italic>\n                      definitions. Demographic and clinical characteristics by type of resistance were compared with appropriate univariate tests. Time to resistance (TTR) and overall survival were analyzed using Kaplan-Meier. To compare the concordance of progression assigned by clinicians and ICR, the positive predictive value (PPV) was calculated in a subset of patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 981 eligible patients, 738 were included. In the adjuvant setting (n=240), 53 (22.1%) patients developed primary resistance and 60 (25.0%) experienced late relapse. In the advanced setting (n=498), 222 (44.6%), 50 (10.0%), and 64 (12.9%) patients developed primary, secondary resistance, and late progression. Type of resistance significantly differed by country, race, type of\n                      <jats:italic>BRAF<\/jats:italic>\n                      mutation, and PD-L1 expression in both settings; and by sex, disease stage and tumor thickness in the adjuvant setting only (p&lt;0.05). Mean (SD) TTR was 47.7 (1.3) and 24.2 (1.0) months in the adjuvant and advanced setting, respectively. Patients with primary resistance had the poorest overall survival. The PPV of progression assigned by clinicians was 87.2% (95% CI 72.6% to 95.7%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study showed that a substantial proportion of patients with melanoma receiving anti-PD-1 therapy in the adjuvant (47.1%) and advanced (67.5%) settings developed resistance or late relapse\/progression, highlighting an unmet medical need. Real-world clinical practice provided a reliable assessment of progression. Factors associated with different types of resistance were identified. Further study is warranted to evaluate their impact on patient risk stratification. (Graphical abstract)<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2025-014564","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T14:45:16Z","timestamp":1772721916000},"page":"e014564","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Resistance to anti-PD-1 immunotherapy for stage III and IV melanoma: a global chart review study"],"prefix":"10.1136","volume":"14","author":[{"given":"Elizabeth M","family":"Gaughan","sequence":"first","affiliation":[{"name":"University of Virginia Cancer Center, Charlottesville, Virginia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miso","family":"Kim","sequence":"additional","affiliation":[{"name":"Seoul National University Hospital, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9146-6807","authenticated-orcid":false,"given":"Ignacio","family":"Mendez","sequence":"additional","affiliation":[{"name":"OXON Epidemiology, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6394-0011","authenticated-orcid":false,"given":"Aparna D","family":"Rao","sequence":"additional","affiliation":[{"name":"Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia"},{"name":"Melanoma Research Victoria, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Wei","sequence":"additional","affiliation":[{"name":"University of California San Francisco, San Francisco, California, USA"},{"name":"San Francisco VA Health Care System, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"So","sequence":"additional","affiliation":[{"name":"University of California San Francisco, San Francisco, California, USA"},{"name":"San Francisco VA Health Care System, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6015-9538","authenticated-orcid":false,"given":"Xiaochen","family":"Zhong","sequence":"additional","affiliation":[{"name":"University of California San Francisco, San Francisco, California, USA"},{"name":"San Francisco VA Health Care System, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0229-8931","authenticated-orcid":false,"given":"Carola","family":"Berking","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Deutsches Zentrum Immuntherapie, Universit\u00e4tsklinikum Erlangen, CCC Erlangen-EMN, Friedrich-Alexander- Universit\u00e4t Erlangen-N\u00fcrnberg, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruixuan","family":"Jiang","sequence":"additional","affiliation":[{"name":"Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc, Rahway, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6145-4426","authenticated-orcid":false,"given":"Tae Min","family":"Kim","sequence":"additional","affiliation":[{"name":"Seoul National University Hospital, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Dalle","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Lyon-Sud, Pierre-Benite Cedex, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9493-0238","authenticated-orcid":false,"given":"Caroline","family":"Robert","sequence":"additional","affiliation":[{"name":"Institut Gustave-Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3593-2890","authenticated-orcid":false,"given":"Sarah","family":"Danson","sequence":"additional","affiliation":[{"name":"Weston Park Cancer Centre, University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salma","family":"Alam","sequence":"additional","affiliation":[{"name":"Mount Vernon Cancer Centre, Northwood, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Charles","sequence":"additional","affiliation":[{"name":"CHU Grenoble, La Tronche, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tessa","family":"Davies","sequence":"additional","affiliation":[{"name":"Velindre University NHS Trust, Cardiff, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Debus","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Nuremberg Hospital, Paracelsus Medical University, Nuremberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Dzienis","sequence":"additional","affiliation":[{"name":"Gold Coast University Hospital, Southport, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricky","family":"Frazer","sequence":"additional","affiliation":[{"name":"Velindre University NHS Trust, Cardiff, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7090-9584","authenticated-orcid":false,"given":"Christoffer","family":"Gebhardt","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3999-5902","authenticated-orcid":false,"given":"Glenn","family":"Geidel","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7575-6230","authenticated-orcid":false,"given":"Jessica C","family":"Hassel","sequence":"additional","affiliation":[{"name":"Heidelberg University, Medical Faculty Heidelberg, Department of Dermatology and National Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ and University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inga","family":"Hansen","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4603-1825","authenticated-orcid":false,"given":"Markus Vincent","family":"Heppt","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Deutsches Zentrum Immuntherapie, Universit\u00e4tsklinikum Erlangen, CCC Erlangen-EMN, Friedrich-Alexander- Universit\u00e4t Erlangen-N\u00fcrnberg, Erlangen, Germany"},{"name":"Dermpath M\u00fcnchen, Laboratory for Dermatopathology, Oral Pathology and Molecular Pathology, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Hildebrandt","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M","family":"Isaacs","sequence":"additional","affiliation":[{"name":"Cleveland Clinic, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koung Jin","family":"Suh","sequence":"additional","affiliation":[{"name":"Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2974-675X","authenticated-orcid":false,"given":"Bhumsuk","family":"Keam","sequence":"additional","affiliation":[{"name":"Seoul National University Hospital, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Jung","family":"Kim","sequence":"additional","affiliation":[{"name":"Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Lesimple","sequence":"additional","affiliation":[{"name":"Centre Eug\u00e8ne Marquis, Rennes-Cedex, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6500-3507","authenticated-orcid":false,"given":"Philippe","family":"Saiag","sequence":"additional","affiliation":[{"name":"Department of General and Oncologic Dermatology, Ambroise Par\u00e9 hospital, APHP, & EA 4340 \u201cBiomarkers in cancerology and hemato-oncology\u201d, UVSQ, Universit\u00e9 Paris-Saclay, Boulogne-Billancourt, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Delibes","sequence":"additional","affiliation":[{"name":"OXON Epidemiology, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2215-4970","authenticated-orcid":false,"given":"Rosemarie","family":"Barnett","sequence":"additional","affiliation":[{"name":"OXON Epidemiology, Madrid, Spain"},{"name":"University of Bath, Bath, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Krepler","sequence":"additional","affiliation":[{"name":"Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc, Rahway, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2573-2630","authenticated-orcid":false,"given":"Kavita","family":"Gandhi","sequence":"additional","affiliation":[{"name":"OXON Epidemiology, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nawab","family":"Qizilbash","sequence":"additional","affiliation":[{"name":"OXON Epidemiology, Madrid, Spain"},{"name":"London School of Hygiene and Tropical Medicine, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5737-9830","authenticated-orcid":false,"given":"Irene M","family":"Shui","sequence":"additional","affiliation":[{"name":"Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc, Rahway, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang-Lin","family":"Tan","sequence":"additional","affiliation":[{"name":"Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc, Rahway, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5344-6645","authenticated-orcid":false,"given":"Ryan J","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Massachusetts General Brigham Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,3,5]]},"reference":[{"key":"2026030506450754000_14.3.e014564.1","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/CMR.0000000000000850","article-title":"Resistance to anti-PD1 therapies in patients with advanced melanoma: systematic literature review and application of the Society for Immunotherapy of Cancer Immunotherapy Resistance Taskforce anti-PD1 resistance definitions","volume":"32","author":"Shui","year":"2022","journal-title":"Melanoma Res"},{"key":"2026030506450754000_14.3.e014564.2","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15133448","article-title":"Medical Needs and Therapeutic Options for Melanoma Patients Resistant to Anti-PD-1-Directed Immune Checkpoint Inhibition","volume":"15","author":"Hassel","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026030506450754000_14.3.e014564.3","doi-asserted-by":"crossref","first-page":"115055","DOI":"10.1016\/j.ejca.2024.115055","article-title":"Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapy","volume":"212","author":"Woodford","year":"2024","journal-title":"Eur J Cancer"},{"key":"2026030506450754000_14.3.e014564.4","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000398","article-title":"Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce","volume":"8","author":"Kluger","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026030506450754000_14.3.e014564.5","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005921","article-title":"Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors","volume":"11","author":"Kluger","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2026030506450754000_14.3.e014564.6","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-16-0287"},{"key":"2026030506450754000_14.3.e014564.7","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14205145","article-title":"Sex-Related Differences in Metastatic Melanoma Patients Treated with Immune Checkpoint Inhibition","volume":"14","author":"Kudura","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2026030506450754000_14.3.e014564.8","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.3390\/cancers15102733","article-title":"Factors Predictive of Primary Resistance to Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer","volume":"15","author":"Huang","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026030506450754000_14.3.e014564.9","doi-asserted-by":"crossref","first-page":"7379","DOI":"10.3390\/curroncol31110544","article-title":"Sex-Related Differences in Immunotherapy Outcomes of Patients with Advanced Non-Small Cell Lung Cancer","volume":"31","author":"Cohen","year":"2024","journal-title":"Curr Oncol"},{"key":"2026030506450754000_14.3.e014564.10","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-15679-x","article-title":"Sex-associated molecular differences for cancer immunotherapy","volume":"11","author":"Ye","year":"2020","journal-title":"Nat Commun"},{"key":"2026030506450754000_14.3.e014564.11","doi-asserted-by":"publisher","DOI":"10.1002\/jnr.20881"},{"key":"2026030506450754000_14.3.e014564.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2010.04.003"},{"key":"2026030506450754000_14.3.e014564.13","doi-asserted-by":"publisher","DOI":"10.1038\/nri2394"},{"key":"2026030506450754000_14.3.e014564.14","doi-asserted-by":"crossref","first-page":"691032","DOI":"10.3389\/fimmu.2021.691032","article-title":"Association of NRAS Mutation With Clinical Outcomes of Anti-PD-1 Monotherapy in Advanced Melanoma: A Pooled Analysis of Four Asian Clinical Trials","volume":"12","author":"Zhou","year":"2021","journal-title":"Front Immunol"},{"key":"2026030506450754000_14.3.e014564.15","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-11-85","article-title":"Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: a study of 522 consecutive cases","volume":"11","author":"Chi","year":"2011","journal-title":"BMC Cancer"},{"key":"2026030506450754000_14.3.e014564.16","doi-asserted-by":"crossref","first-page":"17","DOI":"10.47102\/annals-acadmedsg.V41N1p17","article-title":"Melanoma: differences between Asian and Caucasian patients","volume":"41","author":"Lee","year":"2012","journal-title":"Ann Acad Med Singap"},{"key":"2026030506450754000_14.3.e014564.17","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3922"},{"key":"2026030506450754000_14.3.e014564.18","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.tranon.2019.02.007","article-title":"A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With Advanced or Metastatic Melanoma (KEYNOTE-151)","volume":"12","author":"Si","year":"2019","journal-title":"Transl Oncol"},{"key":"2026030506450754000_14.3.e014564.19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.9258"},{"key":"2026030506450754000_14.3.e014564.20","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02498-y"},{"key":"2026030506450754000_14.3.e014564.21","doi-asserted-by":"crossref","first-page":"HSR23","DOI":"10.6004\/jnccn.2022.7193","article-title":"HSR23-110: Immune Checkpoint Inhibitor (ICI) Treatment After Progression on Anti\u2013PD-1 Therapy in Advanced Melanoma: A Systematic Review of the Literature","volume":"21","author":"Olson","year":"2023","journal-title":"J Natl Compr Canc Netw"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-014564","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T14:45:19Z","timestamp":1772721919000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-014564"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":21,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3,5]]},"published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1136\/jitc-2025-014564"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-014564","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]}}}